Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis Compared to Lucentis Monotherapy in Subjects With Wet Age-related Macular Degeneration - AVANTE Study

Trial Profile

A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis Compared to Lucentis Monotherapy in Subjects With Wet Age-related Macular Degeneration - AVANTE Study

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carotuximab (Primary) ; Ranibizumab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms AVANTE
  • Sponsors Santen Pharmaceutical
  • Most Recent Events

    • 07 Aug 2019 According to a TRACON pharmaceuticals media release, top-line data, including the primary endpoint of mean change in best corrected visual acuity at six months, from this trial are expected in the first half of 2020.
    • 07 Aug 2019 According to a TRACON pharmaceuticals media release, status changed from recruiting to active, no longer recruiting.
    • 28 Feb 2019 According to a TRACON Pharmaceuticals media release, the top-line data from this study is expected in the first half of 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top